Funder: National Institutes of Health
Due Dates: May 7, 2025 (AIDS) | June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | September 7, 2025 (AIDS) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | January 7, 2026 (AIDS) | February 5, 2026 (New) | March 5, 2026 (Renewal/Resubmission/Revision) | May 7, 2026 (AIDS) | June 5, 2026 (New) | July 5, 2026 (Renewal/Resubmission/Revision) | September 7, 2026 (AIDS) | October 5, 2026 (New) | November 5, 2026 (Renewal/Resubmission/Revision) | January 7, 2027 (AIDS) | February 5, 2027 (New) | March 5, 2027 (Renewal/Resubmission/Revision) | May 7, 2027 (AIDS) | June 5, 2027 (New) | July 5, 2027 (Renewal/Resubmission/Revision) | September 7, 2027 (AIDS) | October 5, 2027 (New) | November 5, 2027 (Renewal/Resubmission/Revision) | January 7, 2028 (AIDS)
Funding Amounts: Up to $500,000 direct costs per year, for a maximum project period of 5 years; actual budget should reflect project needs.
Summary: Supports research integrating imaging and fluid-based (liquid biopsy) tumor monitoring during cancer therapy to optimize assessment of treatment response and resistance.
Key Information: Clinical trial proposals are optional; non-domestic (non-U.S.) entities are not eligible to apply.